A New Clinical Trial for Ewing Sarcoma Patients
INTER-EWING-1 is an international trial recruiting newly diagnosed sarcoma patients aged between 2 and 50 years of age.
The trial will examine the effects of changing treatment at three key points:
- Access to a novel agent known as a tyrosine kinase inhibitor
- Optimising radiotherapy doses
- Adding maintenance chemotherapy at the end of other planned treatments
International trials are important for rare diseases like Ewing sarcoma. Not only do they provide access to new treatments but the pooling of patients around the world provides enables trials to recruit quicker. This ultimately speeds up access to new treatment pathways and improves outcomes for Ewing sarcoma patients.
ANZSA Board Director, Associate Professor Marianne Phillips is the National Principal Investigator of INTER EWING-1.
INTER-EWING-1 is clinically driven by ANZSA and ANZCHOG. The trial will be funded by the Australian Government's Medical Research Future Fund (via Canteen), The Kids' Cancer Project, the Cooper Rice-Brading Foundation, the GPA Andrew Ursini Charitable Fund, and the Australian Government's Medical Research Future Fund (through the 2021 Rare Cancers, Rare Diseases and Unmet Need MRF2015073) and Australia New Zealand Children’s Haematology and Oncology Group.